Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis
August 21st 2023John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.
Read More
Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis
August 17th 2023John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.
Read More
Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis
May 11th 2023John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
Read More